TL 13-27 is described in public supplier information as the negative-control compound paired with the multikinase degrader TL 12-186. It is used to help distinguish degradation driven by productive cereblon recruitment from effects arising from kinase-warhead binding or nonspecific chemical exposure. Public summaries do not present TL 13-27 as an active degrader, so it should be treated as a control reagent rather than as a standalone PROTAC tool for target depletion. In experimental design, TL 13-27 supports interpretation of TL 12-186 studies by controlling for target-binding scaffold features while limiting productive E3-mediated ubiquitination. Its value lies in validating cereblon-dependent degradation, assessing off-target phenotypes, separating kinase inhibition from protein depletion, and strengthening proteomic or western-blot workflows that evaluate multikinase PROTAC activity.
Structure of 2250025-90-0
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Target: TL 13-27 is a negative control lacking productive kinase degradation activity.
Binding site: Its kinase-binding moiety can engage kinase ATP-binding regions without productive degradation.
Mechanism of action: TL 13-27 is an inactive negative control for the multitargeted kinase degrader TL 12-186. Although it retains a heterobifunctional PROTAC-like architecture, it does not induce detectable kinase degradation in vitro, making it useful for separating degradation-dependent effects from nonspecific compound exposure. In experimental workflows, TL 13-27 can control for target-ligand binding, linker-related physicochemical properties, CRBN ligand presentation, and cellular treatment conditions. It is particularly valuable in chemoproteomic degrader studies where interpretation requires distinguishing productive ubiquitin-proteasome engagement from simple kinase occupancy or off-target cellular stress.
Applications• PROTAC-Mediated Targeted Degradation: TL 13-27 is designed to facilitate the targeted degradation of specific proteins by harnessing the ubiquitin-proteasome system. This application is crucial for investigating protein function and validating potential therapeutic targets in various cellular contexts.
• Protein Homeostasis Research: Utilizing TL 13-27 allows researchers to study the dynamics of protein homeostasis by selectively degrading proteins of interest. This aids in understanding the role of protein turnover in cellular processes and disease mechanisms.
• Functional Genomics Studies: TL 13-27 can be employed in functional genomics to achieve selective protein knockdown, providing insights into gene function and interactions. This application is vital for elucidating complex biological pathways and networks.
• Drug Discovery and Development: By using TL 13-27 in drug discovery, researchers can identify and validate novel drug targets through precise protein degradation. This approach accelerates the development of innovative therapeutic strategies by focusing on previously undruggable proteins.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.